Susquehanna International Group
IBRX icon

Susquehanna International Group’s ImmunityBio IBRX Stock Holding History

Susquehanna International Group’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.6M Buy
5,683,600
+5,327,700
+1,497% +$36.5M ﹤0.01% 1398
2025
Q4 		$705K Sell
355,900
-822,200
-70% -$1.86M ﹤0.01% 8011
2025
Q3 		$2.9M Buy
1,178,100
+555,400
+89% +$1.43M ﹤0.01% 5043
2025
Q2 		$1.64M Buy
622,700
+182,000
+41% +$489K ﹤0.01% 6216
2025
Q1 		$1.33M Sell
440,700
-72,300
-14% -$219K ﹤0.01% 6537
2024
Q4 		$1.31M Sell
513,000
-23,700
-4% -$98.7K ﹤0.01% 6296
2024
Q3 		$2M Buy
536,700
+29,200
+6% +$135K ﹤0.01% 5270
2024
Q2 		$3.21M Sell
507,500
-610,100
-55% -$4.02M ﹤0.01% 4192
2024
Q1 		$6M Buy
1,117,600
+659,500
+144% +$2.99M ﹤0.01% 3347
2023
Q4 		$2.3M Sell
458,100
-270,300
-37% -$848K ﹤0.01% 5080
2023
Q3 		$1.23M Sell
728,400
-304,900
-30% -$612K ﹤0.01% 6166
2023
Q2 		$2.87M Buy
1,033,300
+970,600
+1,548% +$2.74M ﹤0.01% 4441
2023
Q1 		$114K Sell
62,700
-5,400
-8% -$16.8K ﹤0.01% 11182
2022
Q4 		$345K Buy
68,100
+3,700
+6% +$20.3K ﹤0.01% 8757
2022
Q3 		$320K Buy
64,400
+31,200
+94% +$142K ﹤0.01% 9634
2022
Q2 		$124K Buy
33,200
+20,200
+155% +$81.1K ﹤0.01% 11245
2022
Q1 		$73K Sell
13,000
-39,900
-75% -$245K ﹤0.01% 12103
2021
Q4 		$322K Sell
52,900
-81,200
-61% -$610K ﹤0.01% 10307
2021
Q3 		$1.31M Sell
134,100
-25,200
-16% -$277K ﹤0.01% 6859
2021
Q2 		$2.27M Sell
159,300
-223,300
-58% -$3.69M ﹤0.01% 5625
2021
Q1 		$9.08M Buy
382,600
+129,700
+51% +$3.36M ﹤0.01% 2935
2020
Q4 		$3.37M Buy
252,900
+112,500
+80% +$1.08M ﹤0.01% 4110
2020
Q3 		$974K Buy
140,400
+79,100
+129% +$789K ﹤0.01% 6178
2020
Q2 		$753K Buy
61,300
+39,400
+180% +$222K ﹤0.01% 6511
2020
Q1 		$63K Buy
+21,900
New +$110K ﹤0.01% 9573
2017
Q4 		– Sell
-10,800
Closed -$59K – 9535
2017
Q3 		$59K Sell
10,800
-66,500
-86% -$410K ﹤0.01% 8504
2017
Q2 		$587K Buy
+77,300
New +$334K ﹤0.01% 6342
2017
Q1 		– Sell
-13,800
Closed -$79K – 9380
2016
Q4 		$79K Sell
13,800
-26,500
-66% -$177K ﹤0.01% 9168
2016
Q3 		$314K Sell
40,300
-5,700
-12% -$42.6K ﹤0.01% 6851
2016
Q2 		$286K Buy
46,000
+5,400
+13% +$41.9K ﹤0.01% 7039
2016
Q1 		$334K Buy
40,600
+6,400
+19% +$60.3K ﹤0.01% 7091
2015
Q4 		$593K Sell
34,200
-8,000
-19% -$119K ﹤0.01% 6441
2015
Q3 		$484K Buy
+42,200
New +$921K ﹤0.01% 7186

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Susquehanna International Group's IBRX Position: Q1 2026 in Review

Susquehanna International Group reduced its ImmunityBio (IBRX) stake by 68% in Q1 2026, selling an estimated $16.9M and leaving 1,179,276 shares worth $9.05M. The position accounts for ﹤0.01% of the portfolio, ranked #3271.

Susquehanna International Group first reported a position in IBRX in Q3 2015 and has held it in 38 quarters since. The position peaked at $11.2M in Q1 2021. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Susquehanna International Group held 1,179,276 shares of ImmunityBio worth $9.05M as of Q1 2026.
  • Susquehanna International Group sold 2,475,223 ImmunityBio shares in Q1 2026, an estimated $16.9M.
  • ImmunityBio made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3271 holding.
  • Susquehanna International Group first reported a position in ImmunityBio in Q3 2015 and has held it in 38 quarters since.
  • Susquehanna International Group's ImmunityBio position peaked at $11.2M in Q1 2021.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.